Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Cynosure Group LLC

Cynosure Group LLC decreased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 17.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 6,547 shares of the company’s stock after selling 1,383 shares during the quarter. Cynosure Group LLC’s holdings in Axsome Therapeutics were worth $554,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AXSM. Charles Schwab Investment Management Inc. increased its position in shares of Axsome Therapeutics by 4.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company’s stock worth $28,992,000 after purchasing an additional 12,778 shares during the last quarter. FMR LLC boosted its stake in Axsome Therapeutics by 20.6% during the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares during the period. BNP Paribas Financial Markets increased its position in shares of Axsome Therapeutics by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock valued at $1,234,000 after acquiring an additional 5,737 shares during the last quarter. Captrust Financial Advisors purchased a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at approximately $514,000. Finally, Erste Asset Management GmbH acquired a new position in shares of Axsome Therapeutics in the 3rd quarter worth approximately $986,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $109.75 on Thursday. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The firm has a market capitalization of $5.35 billion, a PE ratio of -18.32 and a beta of 0.88. The business’s fifty day moving average price is $120.62 and its 200 day moving average price is $101.58.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on AXSM. Leerink Partners boosted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, February 10th. Morgan Stanley raised their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $176.00 price target on the stock. Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, Mizuho upped their target price on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, March 27th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $167.64.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.